IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v9y2018i1d10.1038_s41467-018-05764-7.html
   My bibliography  Save this article

Nanomedicines reveal how PBOV1 promotes hepatocellular carcinoma for effective gene therapy

Author

Listed:
  • Yu Guo

    (the First Affiliated Hospital of Sun Yat-Sen University
    School of Materials Science and Engineering of Sun Yat-Sen University)

  • Zhiqiang Wu

    (the First Affiliated Hospital of Sun Yat-Sen University
    Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer)

  • Shunli Shen

    (the First Affiliated Hospital of Sun Yat-Sen University)

  • Ruomi Guo

    (the Third Affiliated Hospital of Sun Yat-Sen University)

  • Jing Wang

    (the First Affiliated Hospital of Sun Yat-Sen University)

  • Weiwei Wang

    (School of Materials Science and Engineering of Sun Yat-Sen University)

  • Kun Zhao

    (the First Affiliated Hospital of Sun Yat-Sen University)

  • Ming Kuang

    (the First Affiliated Hospital of Sun Yat-Sen University)

  • Xintao Shuai

    (the First Affiliated Hospital of Sun Yat-Sen University
    School of Materials Science and Engineering of Sun Yat-Sen University)

Abstract

There exists an urgent medical demand at present to develop therapeutic strategies which can improve the treatment outcome of hepatocellular carcinoma (HCC). Here, we explore the biological functions and clinical significance of PBOV1 in HCC in order to push forward the diagnosis and treatment of HCC. Using theranostical nanomedicines, PBOV1 is verified to be a key oncogene which greatly promotes HCC proliferation, epithelial-to-mesenchymal transition, and stemness by activating the Wnt/β-catenin signaling pathway. Therefore, single-chain antibody for epidermal growth factor receptor (scAb-EGFR)-targeted nanomedicine effectively silencing the PBOV1 gene exhibits potent anticancer effects. In vivo HCC-targeting siRNA delivery mediated by the theranostical nanomedicine remarkably inhibits the tumor growth and metastasis. In addition, the superparamagnetic iron oxide nanocrystals (SPION)-encapsulated nanomedicines possess high MRI detection sensitivity, which endows them with the potential for MRI diagnosis of HCC. This study shows that PBOV1 represents a prognostic biomarker and therapeutic target for HCC.

Suggested Citation

  • Yu Guo & Zhiqiang Wu & Shunli Shen & Ruomi Guo & Jing Wang & Weiwei Wang & Kun Zhao & Ming Kuang & Xintao Shuai, 2018. "Nanomedicines reveal how PBOV1 promotes hepatocellular carcinoma for effective gene therapy," Nature Communications, Nature, vol. 9(1), pages 1-16, December.
    • Handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-05764-7
    DOI: 10.1038/s41467-018-05764-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-018-05764-7
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-018-05764-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Chunping Mao & Fuan Deng & Wanning Zhu & Leiming Xie & Yijun Wang & Guoyin Li & Xingke Huang & Jiahui Wang & Yue Song & Ping Zeng & Zhenpeng He & Jingnan Guo & Yao Suo & Yujing Liu & Zhuo Chen & Mingx, 2024. "In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy," Nature Communications, Nature, vol. 15(1), pages 1-20, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-05764-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.